Sermorelin Biohacker and Longevity Stack Protocol: Doses, Cycles, Labs, and Evidence

What Sermorelin Actually Does at the Pituitary Level

Sermorelin binds GHRH receptors on somatotroph cells in the anterior pituitary, triggering a burst of endogenous GH that mirrors the natural nocturnal pulse. This is mechanistically different from injecting recombinant human GH (rhGH): sermorelin preserves the negative-feedback loop through somatostatin, which means the pituitary can still suppress GH release if levels run too high.

That feedback preservation is the core reason longevity physicians prefer sermorelin over rhGH for adults who are not classically GH-deficient. Supraphysiologic GH from exogenous rhGH bypasses this loop entirely, raising concerns about insulin resistance and, theoretically, cancer-growth promotion at high doses.

The GH-IGF-1 Axis and Why It Declines

After age 30, average GH secretion drops roughly 14% per decade, a process called somatopause [1]. IGF-1 (insulin-like growth factor 1), the primary downstream mediator of GH action, falls in parallel. Low IGF-1 correlates with reduced lean mass, increased visceral fat, worse sleep quality, and poorer cardiovascular risk profiles in observational cohort data [2].

Sermorelin targets this decline at the source, stimulating the pituitary rather than adding exogenous hormone to the bloodstream.

How Quickly Does IGF-1 Respond?

In a placebo-controlled trial of 21 adults with GH deficiency receiving sermorelin 0.03 mg/kg/day subcutaneously, mean serum IGF-1 rose significantly within 8 weeks and continued rising through week 16 [3]. Observational practitioner data suggest a 20 to 40% IGF-1 increase from baseline at 8 to 12 weeks in adults with age-related low-normal GH secretion, though this figure has not been confirmed in a large RCT.

Evidence Quality: What the Data Actually Support

Longevity influencers and biohackers often cite sermorelin as if it were fully validated for healthy aging. The evidence is more tiered than that, and any honest protocol should label each claim clearly.

Tier 1: RCT-Level Evidence

Corpas et al. (1993) conducted a 6-month double-blind, placebo-controlled crossover RCT in healthy men aged 60 to 70 (N=8 per group). Nightly subcutaneous sermorelin at 2 mcg/kg increased mean IGF-1 by approximately 30% over baseline, improved sleep stage III-IV duration, and produced modest gains in lean body mass. The study was small, but it remains the most controlled longevity-adjacent sermorelin trial in healthy older adults [4].

A separate RCT by Vittone et al. (1997) in older men (N=17) showed that sermorelin raised IGF-1 significantly (P<0.01) versus placebo and improved body composition metrics at 6 months, with no significant adverse metabolic effects at the doses used [3].

Tier 2: Observational and Registry Data

Larger observational series from academic GH-deficiency registries (such as KIMS and HypoCCS) document the body-composition and quality-of-life benefits of restoring GH-axis activity in adults, although these registries used rhGH, not sermorelin, as the intervention [5]. The mechanistic rationale extends to sermorelin since IGF-1 normalization is the shared endpoint, but this is an inference, not direct evidence.

Tier 3: Practitioner Experience and Expert Opinion

The "Attia/Huberman/Brecka tier" framing in the longevity community reflects practitioner-level consensus built from patient outcomes, not peer-reviewed trials. Physicians who prescribe sermorelin off-label for adults report improvement in sleep, recovery, and body composition, but published case series on this population are sparse. Every protocol element beyond the Corpas and Vittone trials should be treated as plausible but not confirmed.

The Standard Longevity Stack Protocol

Dose Selection

The most commonly prescribed starting dose in longevity medicine practice is 100 to 200 mcg subcutaneously at bedtime. Some practitioners escalate to 300 mcg in adults whose IGF-1 response is blunted at 12 weeks. Doses above 300 mcg in adults add side-effect burden without proportional IGF-1 gain in most practitioners' experience (Tier 3 evidence).

The FDA-approved pediatric dose is weight-based (approximately 30 mcg/kg/day), which in adults often translates to 2,000+ mcg daily. Longevity protocols intentionally use sub-pharmacologic doses to avoid tachyphylaxis and preserve receptor sensitivity.

Injection Timing

Sermorelin should be injected 30 to 60 minutes after the last meal of the day and as close to sleep onset as possible. This aligns the drug's pituitary stimulation with the endogenous nocturnal GH surge, which peaks in the first two hours of non-REM slow-wave sleep. Eating within 30 minutes of injection raises somatostatin tone via elevated insulin, blunting the GH response.

Injection Site and Technique

Standard subcutaneous injection into the periumbilical abdomen or lateral thigh, using a 29 to 31 gauge, 0.5-inch insulin syringe. Rotate sites. Reconstituted sermorelin is typically stored at 2 to 8°C and used within 30 days. Review the FDA Geref prescribing information for reconstitution specifications [6].

Cycle Length and Off-Periods

Most longevity protocols run 3 to 6 months of daily sermorelin followed by a 4 to 8-week washout. The rationale for cycling is receptor downregulation prevention and restoration of baseline pituitary sensitivity. There is no controlled trial data specifically on cycling strategy in adults; this reflects practitioner consensus (Tier 3).

A typical first-year schedule might look like:

• Months 1 to 4: sermorelin 100 to 200 mcg nightly
• Months 5 to 5.5: washout (no sermorelin)
• Months 6 to 9: resume at 150 to 300 mcg nightly based on IGF-1 response
• Month 10 onward: individualize based on labs

Stacking Sermorelin with Other Peptides

The longevity community frequently pairs sermorelin with a GHRP (growth hormone releasing peptide) to produce synergistic GH pulses. The two most studied GHRP options are ipamorelin and GHRP-2.

Sermorelin Plus Ipamorelin

Ipamorelin is a selective GH secretagogue with a favorable side-effect profile: it does not significantly raise cortisol or prolactin at standard doses, unlike older GHRPs such as GHRP-6 [7]. The combination of a GHRH analog (sermorelin) with a GHRP (ipamorelin) produces additive or supra-additive GH release because they act on different receptors on the same somatotroph cell.

A common pairing:

• Sermorelin 100 to 200 mcg + ipamorelin 100 to 200 mcg, co-injected subcutaneously at bedtime.

This combination has become the de facto starting point for longevity physicians who want meaningful IGF-1 elevation without the risks of rhGH.

Sermorelin Plus CJC-1295 No-DAC

CJC-1295 no-DAC (also called modified GRF 1-29) is a stabilized GHRH analog with a slightly longer half-life than sermorelin (approximately 30 minutes vs. 10 to 12 minutes for sermorelin). Some practitioners substitute CJC-1295 no-DAC for sermorelin or use them in rotation across a cycle. The evidence base for this substitution is Tier 3.

Adding BPC-157 to the Stack

BPC-157 (body protection compound 157) is a 15-amino-acid peptide derived from gastric juice protein BPC. It does not act on the GH axis but is stacked by longevity biohackers for its proposed tissue-repair and gut-integrity effects. Rodent studies suggest anti-inflammatory and angiogenic properties [8], but no human RCT has validated these effects. If BPC-157 is included, it is typically injected separately (different syringe, separate site) since it serves a completely different mechanism.

What Not to Stack

Sermorelin should not be combined with exogenous rhGH at standard doses. The two mechanisms partially overlap, and rhGH at longevity doses already bypasses the feedback loop that makes sermorelin safer. Most conservative longevity physicians choose one approach or the other.

Monitoring Labs: The Full Panel

Monitoring is not optional in a responsible protocol. The Endocrine Society's clinical practice guideline on adult GH deficiency states that "IGF-1 should be measured 1 to 2 months after dose adjustment to guide titration," a principle that applies to sermorelin off-label use as well [9].

Baseline Labs (Before Starting)

| Lab | Why It Matters | |---|---| | Serum IGF-1 | Establishes GH-axis function baseline | | Fasting glucose and HbA1c | GH is insulin-antagonizing; screen before starting | | Fasting insulin / HOMA-IR | Insulin sensitivity baseline | | TSH, free T4 | Hypothyroidism suppresses GH response | | Testosterone (total/free) | Low T blunts body-composition response | | CBC, CMP | General safety baseline | | PSA (men >40) | GH may influence prostate tissue | | Sleep study if snoring/OSA symptoms | Untreated sleep apnea is a contraindication |

On-Therapy Monitoring

• Serum IGF-1 at 8 weeks: The primary titration signal. Target mid-to-upper age-adjusted normal range. Keep IGF-1 below the upper limit of normal (roughly 250 to 350 ng/mL for adults aged 30 to 60, lab-dependent).
• Fasting glucose at 8 weeks: GH is counter-regulatory. If fasting glucose rises above 100 mg/dL, assess dietary factors and consider dose reduction.
• Repeat full panel at 6 months: Before any cycle decision.
• Annual IGF-1 and metabolic panel: For ongoing off-label maintenance.

The Endocrine Society guideline specifically warns that "overtreatment, defined as IGF-1 above the age-adjusted normal range, is associated with edema, arthralgia, carpal tunnel syndrome, and potentially increased cancer risk" [9]. Stay within the range. This is not a situation where higher is better.

Expected Timeline of Outcomes

Based on the Corpas and Vittone RCTs and practitioner-level observational data, a realistic timeline looks like this:

Weeks 1 to 3: Improved sleep quality, particularly deeper slow-wave sleep, is the most commonly reported early effect. This is consistent with GH's established role in sleep architecture [4].

Weeks 4 to 8: Subjective improvement in recovery from exercise, reduced joint discomfort in some users (though this is anecdotal).

Weeks 8 to 12: Measurable IGF-1 rise (expect 20 to 40% from baseline if baseline was low-normal). Body composition changes begin but are not yet visible in most adults.

Months 3 to 6: Modest lean mass gain and visceral fat reduction are reported in the RCT literature. Corpas et al. Documented a 1.7 kg lean mass increase at 6 months in men aged 60 to 70 receiving nightly sermorelin [4]. Expect similar or attenuated results in adults starting from a higher baseline IGF-1.

Beyond 6 months: Sustained improvements in body composition require sustained therapy. Benefits may partially reverse during washout periods, which is one reason some practitioners extend cycles to 6 months before rotating off.

Safety Profile and Contraindications

Sermorelin has a favorable short-term safety record within FDA-approved pediatric dosing. The adult longevity off-label safety profile is less formally characterized but generally reported as mild.

Common Side Effects

• Injection site reactions (redness, mild irritation): up to 17% in trial populations [3]
• Facial flushing immediately post-injection: transient, mechanism unclear
• Headache: less than 10% in RCT data
• Transient nausea

More Serious Concerns

• Fluid retention and edema: GH-driven sodium retention. More common above 300 mcg/day.
• Carpal tunnel symptoms: Median nerve compression from fluid retention. Dose-reduce promptly if tingling develops.
• Hyperglycemia: GH opposes insulin at target tissues. Monitor fasting glucose, especially in pre-diabetic patients.
• Theoretical cancer promotion: IGF-1 is a mitogen. Patients with active or recent malignancy should not use sermorelin. This caution is extrapolated from rhGH oncology literature, not sermorelin-specific RCT data [10].

Absolute Contraindications

1. Active malignancy or recent history (<5 years remission for most solid tumors)
2. Untreated obstructive sleep apnea
3. Pituitary tumor or history of cranial irradiation
4. Pregnancy or active breastfeeding
5. Hypersensitivity to sermorelin or any component of the formulation

Regulatory Status and Sourcing Considerations

The FDA approved sermorelin acetate (Geref, Serono) for pediatric GH deficiency. Adult use is off-label. Geref is no longer commercially marketed in the United States, so adult patients obtain sermorelin through compounding pharmacies operating under 503A or 503B status.

In 2023, the FDA placed sermorelin on the Category 2 list under 503A compounding rules, meaning its compounded status is under ongoing regulatory review [6]. Patients should confirm their compounding pharmacy's compliance with current FDA guidance before starting. Sourcing from unregulated online vendors carries risks of underdosed, mislabeled, or contaminated product.

The Endocrine Society's position on GH-axis peptides in healthy aging adults is cautious: "GH treatment in healthy older adults is not recommended outside of clinical trials" [9]. Off-label sermorelin use falls into that same category of informed clinical judgment, not standard of care.

The Physician's Role in This Protocol

No part of this protocol should be self-administered without physician oversight. A prescribing clinician should:

1. Review baseline labs and rule out contraindications
2. Confirm the diagnosis of low-normal GH secretion (low IGF-1 for age) before prescribing
3. Select the dose based on IGF-1 target range, not patient preference
4. Monitor IGF-1 at 8 weeks and adjust
5. Discontinue immediately if IGF-1 exceeds the upper age-adjusted normal limit

Longevity biohackers who self-source peptides and skip monitoring are accepting risks that are not quantified in any published dataset. The feedback loop that makes sermorelin theoretically safer than rhGH only works if someone is actually reading the IGF-1 labs.